公开(公告)号：WO9613259A2

公开(公告)日：1996-05-09

申请号：PCT/US9513882

申请日：1995-10-26

Applicant: COR THERAPEUTICS INC

Inventor： GIESE NEILL A ,  LOKKER NATHALIE

IPC: C12N9/99 ,  A61K31/365 ,  A61K31/366 ,  A61P35/02 ,  C07D313/00

CPC classification number: A61K31/366 ,  A61K31/365

Abstract: A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a molecule of formula (I) wherein R1 is H, lower alkyl, or lower alkanoyl; R2 is H, lower alkyl, or lower alkanoyl; R3 and R4 together represent a cis double bond or -O- or each of R3 and R4 independently represents H or OR; R5 is =O, =S, or -H, -OR; R6 and R7 together represent a double bond or -O- or each of R6 and R7 independently represents H or OR; R8 and R9 together represent a double bond or -O- or each of R8 and R9 independently represents H or OR; and each R independently represents H, lower alkyl, or lower alkanoyl.

Abstract translation: 公开了选择性抑制激酶的方法，其包括将含有激酶的组合物与式（I）分子（其中R 1为H，低级烷基或低级烷酰基）接触; R2是H，低级烷基或低级烷酰基; R3和R4一起表示顺式双键或-O-或R 3和R 4各自独立地表示H或OR; R5为= O，= S或-H，-OR; R6和R7一起表示双键或-O-或R6和R7各自独立地表示H或OR; R8和R9一起表示双键或-O-或R8或R9各自独立地表示H或OR; 并且每个R独立地表示H，低级烷基或低级烷酰基。

公开(公告)号：WO1995003318A1

公开(公告)日：1995-02-02

申请号：PCT/US1994008536

申请日：1994-07-26

Applicant: COR THERAPEUTICS

Inventor： COR THERAPEUTICS ,  SCARBOROUGH, Robert, M. ,  SUNDELIN, Johan

IPC: C07H21/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K48/00 ,  C07K7/08 ,  C07K14/723

Abstract: The DNA encoding the C140 cell surface receptor has been cloned and sequenced. The availability of this DNA permits the recombinant production of the C140 receptor which can be produced at cell or oocyte surfaces and is useful in assay systems both for the detection of substances which affect its activity, including agonists and antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in these assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof.

Abstract translation: 编码C140细胞表面受体的DNA已被克隆并测序。 该DNA的可用性允许重组产生可在细胞或卵母细胞表面产生的C140受体，并且可用于检测影响其活性的物质（包括激动剂和拮抗剂）的测定系统中。 此外，阐明C140受体的结构允许设计可用于这些测定中的激动剂和拮抗剂化合物。 C140受体的可用性还允许产生与受体本身或其特定区域特异性免疫反应的抗体。

公开(公告)号：WO1993018782A1

公开(公告)日：1993-09-30

申请号：PCT/US1993002203

申请日：1993-03-11

Applicant: COR THERAPEUTICS, INC. ,  SINHA, Uma ,  WOLF, David, L.

Inventor： COR THERAPEUTICS, INC.

IPC: A61K35/78

CPC classification number: C12N9/6432 ,  A61K38/1709 ,  A61K38/47 ,  C07K14/42 ,  C07K14/745 ,  C07K16/36 ,  C12Y304/21006 ,  Y10S436/827

Abstract: Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an alpha 2-6 linkage are able to inhibit the conversion of human Factor X to human Factor Xa. These reagents (SA/Gal/GalNAc binding reagents) as well as other strategies for inhibiting the conversion of Factor X to Factor Xa are useful in treating thrombosis, inflammation and other conditions associated with excess thrombin activity.

Abstract translation: 特异性结合碳水化合物靶标的试剂能够抑制人因子X向人因子Xa的转化，其中唾液酸在糖苷的非还原性末端通过α2-6键连接到半乳糖或半乳糖胺残基。 这些试剂（SA / Gal / GalNAc结合试剂）以及抑制因子X转化成因子Xa的其它策略可用于治疗血栓形成，炎症和与过量凝血酶活性相关的其它病症。

公开(公告)号：WO1992008472A1

公开(公告)日：1992-05-29

申请号：PCT/US1991008516

申请日：1991-11-14

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  SCARBOROUGH, Robert, M.

IPC: A61K37/00

CPC classification number: C07K14/75 ,  A61K38/00 ,  C07K14/46 ,  C07K16/18 ,  Y10S530/856

Abstract: Platelet antiadhesives (PAA) which are useful as antithrombotics are obtainable from snake venoms which have been identified using an assay which measures the ability of the venom to inhibit ristocetin- or botrocetin-induced agglutination of platelets in the presence of von Willebrand Factor. The antiadhesives of the invention are 20-24 kd dimers of smaller peptides, or effective portions thereof. Antibodies to these antiadhesives are also prepared and are useful in assays for PAA and for screening expression libraries for PAA encoding DNA.

Abstract translation: 可用作抗血栓药物的血小板抗粘附剂（PAA）可从蛇毒获得，蛇毒使用测定毒素在血管性血友病因子存在下抑制瑞斯托菌素或博西汀诱导血小板凝集的能力的测定法。 本发明的抗粘附剂是较小肽的20-24kD二聚体或其有效部分。 还制备了这些抗粘附剂的抗体，并且可用于PAA的测定和用于筛选编码DNA的PAA的表达文库。

公开(公告)号：WO1990015620A1

公开(公告)日：1990-12-27

申请号：PCT/US1990003417

申请日：1990-06-15

Applicant: COR THERAPEUTICS, INC.

Inventor： COR THERAPEUTICS, INC. ,  SCARBOROUGH, Robert, M. ,  WOLF, David, Lawrence ,  CHARO, Israel, F.

IPC: A61K37/62

CPC classification number: C07K14/75 ,  A61K38/12 ,  A61K38/1703 ,  A61K38/57 ,  C07K14/46 ,  C07K14/755 ,  C07K14/78

Abstract: An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K* -(G/Sar)-D wherein K* is a modified lysyl residue of the formula R 2 N(CH2)4CHNHCO- wherein each R is independently H, alkyl(1-6C) or at most one R is R -C=NR wherein R is H, alkyl(1-6C), phenyl or benzyl, or is NR in which each R is independently H or alkyl(1-6C) and R is H, alkyl(1-6C), phenyl or benzyl, or R -C=NR is a radical selected from the group consisting of (a), (b), (c) and (d) where m is an integer of 2-3, and each R is independently H or alkyl(1-6C); and wherein one or two (CH2) may be replaced by O or S provided said O or S is not adjacent to another heteroatom are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.

Abstract translation: 描述了基于特异性受体结合筛选蛇毒用于存在或不存在血小板聚集抑制剂（PAI）的测定法。 使用该测定，完成了广泛的蛇毒样品中PAIs的鉴定和表征。 描述和表征了来自这些活性蛇毒中的几种的分离和纯化的PAI。 另外，缺少Arg-Gly-Asp（RGD）粘附序列但含有K * - （G / Sar）-D的PAI，其中K *是式R 1 N 2（CH 2）4 CHNHCO- 其中每个R 1独立地是H，烷基（1-6C）或至多一个R 1是R 2 -C = NR 3，其中R 2是H，烷基（1-6C） 或苯基或苄基，或为NR 4，其中每个R 4独立地为H或（1-6C）烷基，R 3为H，烷基（1-6C），苯基或苄基， 2 -C-NR 3是选自（a），（b），（c）和（d）中的基团，其中m是2-3的整数，并且每个R 5是 独立地是H或（1-6C）烷基; 并且其中一个或两个（CH 2）可以被O或S替代，条件是所述O或S不与另一个杂原子相邻，并且显示出特异性抑制纤维蛋白原或血管性血友病因子与GP IIb-IIIa的结合。

公开(公告)号：US20040072757A1

公开(公告)日：2004-04-15

申请号：US10712332

申请日：2003-11-13

Applicant: COR Therapeutics, Inc.

Inventor： David L. Wolf ,  Uma Sinha

IPC: A61K038/37

CPC classification number: C12N9/6464 ,  A61K38/00 ,  C07K14/745 ,  C12N9/6432 ,  C12N9/647 ,  C12Y304/21006 ,  C12Y304/21069

Abstract: Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

Abstract translation: 短暂失活的血液因子的类似物可用于治疗以血栓形成为特征的疾病。 此外，在血清中产生活性血因子但具有延长半衰期的活化血液因子的修饰形式可用于治疗嗜血性病症。 血液因子的这些修饰形式可以是在体内缓慢脱酰基化的酰化形式。

公开(公告)号：US20030228307A1

公开(公告)日：2003-12-11

申请号：US10439168

申请日：2003-05-16

Applicant: COR Therapeutics Inc. ,  Millennium Pharmaceuticals Inc.

Inventor： Vanitha Ramakrishnan ,  Maria Amelia Escobedo ,  Larry J. Fretto

IPC: A61K039/395 ,  C07K016/44 ,  C07K016/28

CPC classification number: C07K16/2863 ,  A61K38/00 ,  C07K14/71 ,  C07K2317/34 ,  C07K2317/73

Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

Abstract translation: 本发明涉及特异性结合人β型PDGF受体的细胞外结构域的免疫球蛋白多肽。 免疫球蛋白多肽与受体的结合抑制PDGF诱导（或刺激的）受体活化，如通过受体磷酸化和二聚化的抑制以及通过抑制PDGF介导的有丝分裂发生，趋化性和显示人PDGF型β受体的细胞的迁移所表明的 在细胞表面。 编码免疫球蛋白多肽的核酸也包含在本发明中。 免疫球蛋白多肽具有诊断和治疗用途。

公开(公告)号：US20030135036A1

公开(公告)日：2003-07-17

申请号：US10212499

申请日：2002-08-06

Applicant: COR Therapeutics Inc., a corporation of the State of California

Inventor： Francois Lanza ,  David R. Phillips ,  Jean-Pierre Cazenave

IPC: C12Q001/68 ,  A61K038/17 ,  C07K014/47 ,  C12P021/02 ,  C12N005/06

CPC classification number: C07K14/705 ,  A61K38/00

Abstract: This invention relates to the glycoprotein v gene. Specifically, this invention discloses the sequence and structure of the glycoprotein v gene and the amino acid sequence of the glycoprotein v polypeptide. In addition, the evolutionary relationship of the glycoprotein v gene with other glycoproteins is described and several uses of the isolated glycoprotein v gene are shown.

Abstract translation: 本发明涉及糖蛋白v基因。 具体地说，本发明公开了糖蛋白v基因的序列和结构以及糖蛋白v多肽的氨基酸序列。 此外，描述了糖蛋白v基因与其他糖蛋白的进化关系，并显示了分离的糖蛋白v基因的几种用途。

公开(公告)号：US20020164698A1

公开(公告)日：2002-11-07

申请号：US09991888

申请日：2001-11-26

Applicant: COR Therapeutics, Inc.

Inventor： Shengfeng Li ,  David R. Phillips

IPC: C12N009/12 ,  C12P021/02 ,  C12N001/21 ,  C12N005/06 ,  C07H021/04

CPC classification number: C07K14/47 ,  A61K38/00

Abstract: The present invention provides the amino acid and nucleotide sequence of a protein that binds to null3 integrins, nullIIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling

Abstract translation: 本发明提供了结合β3整联蛋白，αIIb和Src激酶并参与整联蛋白介导的信号传导的蛋白质的氨基酸和核苷酸序列。 基于该公开内容，本发明提供了用于鉴定阻断整联蛋白介导的信号传导的试剂的方法，使用阻断整联蛋白介导的信号传导来调节生物学和病理学过程的试剂的方法以及阻断整联蛋白介导的信号传导

公开(公告)号：US20250099657A1

公开(公告)日：2025-03-27

申请号：US18975026

申请日：2024-12-10

Applicant: X-Cor Therapeutics Inc.

Inventor： Steven Paul KELLER ,  Brian Yale CHANG ,  Jayon WANG

IPC: A61M1/16 ,  A61M1/36 ,  B01D19/00 ,  B01D61/24 ,  B01D63/02

Abstract: Systems, devices, and methods are provided for removing carbon dioxide from a target fluid, such as, for example, blood, to treat hypercarbic respiratory failure or another condition. A device is provided including first and second membrane components for removing dissolved gaseous carbon dioxide and bicarbonate from the fluid, which can be done simultaneously. The device can be in the form of a cartridge configured for use in a dialysis system. A method of treatment is also provided, involving drawing blood from a patient and bringing the patient's blood in contact with a first membrane component having a sweep gas passing therethrough, and a second membrane component having a dialysate passing therethrough. The dialysate's composition can be selected such that charge neutrality is maintained.